NI201100031A - Métodos para tratar la talasemia. - Google Patents
Métodos para tratar la talasemia.Info
- Publication number
- NI201100031A NI201100031A NI201100031A NI201100031A NI201100031A NI 201100031 A NI201100031 A NI 201100031A NI 201100031 A NI201100031 A NI 201100031A NI 201100031 A NI201100031 A NI 201100031A NI 201100031 A NI201100031 A NI 201100031A
- Authority
- NI
- Nicaragua
- Prior art keywords
- thalasemia
- treat
- methods
- thalassemia
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
En la presente invención se proporciona un método para tratar, mejorar, o retrasar al menos un síntoma de un trastorno sanguíneo genético, por ejemplo, anemia drepanocítica o talasemia, en un paciente que lo necesite, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2. También se proporciona en parte un método para reducir un bazo dilatado en un paciente que padece talasemia, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8623308P | 2008-08-05 | 2008-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100031A true NI201100031A (es) | 2011-09-26 |
Family
ID=41581108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100031A NI201100031A (es) | 2008-08-05 | 2011-02-02 | Métodos para tratar la talasemia. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110269721A1 (es) |
| EP (1) | EP2355827A2 (es) |
| JP (1) | JP2011530517A (es) |
| KR (1) | KR20110053347A (es) |
| CN (1) | CN102112131A (es) |
| AU (1) | AU2009279825A1 (es) |
| BR (1) | BRPI0917575A2 (es) |
| CA (1) | CA2732791A1 (es) |
| CL (1) | CL2011000242A1 (es) |
| CO (1) | CO6351728A2 (es) |
| CR (1) | CR20110115A (es) |
| DO (1) | DOP2011000044A (es) |
| EC (1) | ECSP11010847A (es) |
| IL (1) | IL211061A0 (es) |
| MA (1) | MA32611B1 (es) |
| MX (1) | MX2011001426A (es) |
| NI (1) | NI201100031A (es) |
| RU (1) | RU2011108563A (es) |
| SV (1) | SV2011003823A (es) |
| WO (1) | WO2010017122A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809614B1 (en) | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
| CA2578283A1 (en) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| NZ611654A (en) * | 2010-12-03 | 2015-08-28 | Ym Biosciences Australia Pty | Treatment of jak2-mediated conditions |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| CN103664799A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| EP2970205B1 (en) * | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺 |
| MA44666A (fr) * | 2016-04-15 | 2019-02-20 | Epizyme Inc | Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2 |
| WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| AU2018254577A1 (en) | 2017-04-21 | 2019-12-05 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| CA3079412A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| JP2021524835A (ja) | 2018-04-05 | 2021-09-16 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | Ａｘｌキナーゼ阻害剤およびその使用 |
| MX2020010556A (es) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| CN112778282B (zh) | 2021-01-06 | 2022-07-22 | 温州医科大学 | 一种嘧啶类小分子化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
-
2009
- 2009-08-03 CA CA2732791A patent/CA2732791A1/en not_active Abandoned
- 2009-08-03 BR BRPI0917575A patent/BRPI0917575A2/pt not_active IP Right Cessation
- 2009-08-03 JP JP2011522136A patent/JP2011530517A/ja active Pending
- 2009-08-03 MX MX2011001426A patent/MX2011001426A/es not_active Application Discontinuation
- 2009-08-03 AU AU2009279825A patent/AU2009279825A1/en not_active Abandoned
- 2009-08-03 WO PCT/US2009/052544 patent/WO2010017122A2/en active Application Filing
- 2009-08-03 RU RU2011108563/15A patent/RU2011108563A/ru not_active Application Discontinuation
- 2009-08-03 US US13/057,133 patent/US20110269721A1/en not_active Abandoned
- 2009-08-03 KR KR1020117005224A patent/KR20110053347A/ko not_active Application Discontinuation
- 2009-08-03 CN CN2009801303954A patent/CN102112131A/zh active Pending
- 2009-08-03 EP EP09741504A patent/EP2355827A2/en not_active Withdrawn
-
2011
- 2011-02-01 SV SV2011003823A patent/SV2011003823A/es not_active Application Discontinuation
- 2011-02-02 NI NI201100031A patent/NI201100031A/es unknown
- 2011-02-03 IL IL211061A patent/IL211061A0/en unknown
- 2011-02-03 DO DO2011000044A patent/DOP2011000044A/es unknown
- 2011-02-04 CL CL2011000242A patent/CL2011000242A1/es unknown
- 2011-02-28 EC EC2011010847A patent/ECSP11010847A/es unknown
- 2011-03-02 CR CR20110115A patent/CR20110115A/es not_active Application Discontinuation
- 2011-03-04 MA MA33672A patent/MA32611B1/fr unknown
- 2011-03-04 CO CO11026653A patent/CO6351728A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2732791A1 (en) | 2010-02-11 |
| RU2011108563A (ru) | 2012-09-10 |
| KR20110053347A (ko) | 2011-05-20 |
| WO2010017122A3 (en) | 2010-04-08 |
| CR20110115A (es) | 2011-06-03 |
| JP2011530517A (ja) | 2011-12-22 |
| SV2011003823A (es) | 2011-08-15 |
| IL211061A0 (en) | 2011-04-28 |
| EP2355827A2 (en) | 2011-08-17 |
| BRPI0917575A2 (pt) | 2019-09-24 |
| ECSP11010847A (es) | 2011-07-29 |
| AU2009279825A1 (en) | 2010-02-11 |
| MA32611B1 (fr) | 2011-09-01 |
| CO6351728A2 (es) | 2011-12-20 |
| DOP2011000044A (es) | 2011-04-30 |
| CN102112131A (zh) | 2011-06-29 |
| WO2010017122A2 (en) | 2010-02-11 |
| MX2011001426A (es) | 2011-03-21 |
| US20110269721A1 (en) | 2011-11-03 |
| CL2011000242A1 (es) | 2011-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201100031A (es) | Métodos para tratar la talasemia. | |
| CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| MX2012000817A (es) | Tratamiento para desordenes del higado con inhibidores pi3k. | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| UA104447C2 (uk) | Тіазолопіридинові сполуки, що модулюють сиртуїн | |
| EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
| MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| TN2012000270A1 (en) | Methods and low dose regimens for treating red blood cell disorders | |
| MX2011006084A (es) | Isoindolinona y analogos relacionados como moduladores de sirtuina. | |
| BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
| WO2009026446A8 (en) | Hdac inhibitors | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| EA200970436A1 (ru) | Соединения карбамата для лечения депрессии | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| EA201100187A1 (ru) | Селективные ингибиторы ммр-12 и ммр-13 на основе гидроксамовой кислоты | |
| WO2006138243A3 (en) | Inhibition of creatine uptake to promote weight loss | |
| IL198396A0 (en) | Methods for treating disruptive behavior disorders | |
| WO2010048264A3 (en) | Methods and compositions for the treatment of immunoinflammatory disorders |